A new treatment called endoscopic duodenal mucosal resurfacing (DMR), combined with a glucagon-like peptide (GLP)-1 receptor agonist medication, has been shown to improve glycemic control in patients with type 2 diabetes, and possibly could enable them to discontinue insulin therapy.  Read more